Suggestions on wording your Qs:
1. (by stockholder101):
What is the timeline on the first discovery... Just some indication that an analysis of DNA is successful in determining the effects of drug "X" on a individual "A." In the latest press release they say 'soon.' Is 'soon' a week, month, 6 months. Well, it's just something all investors want to know, I'm sure.
What are the revenue streams you anticipate to generate in the short term (within one year), medium term (2 to 3 years) and the long term? Would it be possible to predict the timeline and the rate of your discoveries? What are the revenue generating products or patents or services that are currently available, and in the pipeline?
3. (WITTY38)
MY QUESTION: Dr. Frudakis has made the comment that DNAPrint will someday be a Fortune 500 Company. To accomplish that, like every other Fortune 500 Company, you will need a high profile CEO (not just a Chief Scientific Officer) to take the company to the next level. At what point do you intend to hire such a person?
(This question as it now stands may be construed as insulting and calling into question the caliber of Dr. T. Frudakis. "Who is better than a person who leads the effort by building a team to get the job done, acquire finances, is technically excellent, understands the firm inside out, is passionately committed to the success of the firm, and is well positioned to raise the profile of the firm by portraying the products, services, and potential both to the public and the potential partners?" may be the rejoinder to this question.). If you have any questions about marketing talent, you may wish to rephrase this question to ask if there are plans to add marketing talent and what kind of qualifications the management would like to see in such a person. If you want to question the role of Carl Smith (who has sales and marketing background), you may ask that directly. If you wish to stick to the original question, you may be better off asking whether Dr. T. Frudakis is planning to divest his responsibilties as CEO to devote more time to the scientfic research/endeavors.
4. (stockholder101)
After receiving the $350,000 from Orchid, how much time do they have before additional funding is necessary? Could they discover something soon enough or use their DNA sequencing product to fund continued research until profitability?
What are your current "cash burn" rates for the current year and the next year? (At these rates, how long will the current cash reserves last?). What are the revenues projected to be generated and the cash reserves on hand currently? How much funding(and in how many rounds) is management expecting to raise prior to moving to NASDAQ listing from the OTC? What are the major (items of expenditure/capital investment)allocations planned over the next two years? (The part of the question "Could they discover something soon enough or use their DNA sequencing product to fund continued research until profitability?" would be answered in Q 1 above if and when you ask about projected revenue streams.)
5. (stockholder101)
Does anybody remember the name of the small company DNAP put $2,000,000 into as an investment (From the 8K). Why did they put so much money into this company? How will this help DNAP's future?
What is the significance of the dealings/investments in CYLC, and SDE Holdings, and how did/would it help DNAP? What is the role of Tampa Bay Financial (TBF) in the running of DNAP, and did the two firms SDE Holdings and CYLC have dealings or business relations with TBF or its management? What other investments is DNAP contemplating or has already made in any other companies? Does the management or personnel of TBF, CYLC, or SDE Holdings have any role in ongoing DNAP operations?
************************************************************
I am just a small investor and am long DNAP (250K shares). I have suggested the above modifications in the hope that they would trigger some more thoughts, and I request you to consider the above in the spirit the suggestions were made.
I have some more questions of some passing interest:
* Has TBF ever successfully taken a company public? (if yes, what are the names of those firms?).
* Does DNAP management anticipate or plan to enlist the help of TBF in going public (both NASDAQ OTC and later NASDAQ)?
* What has TBF's investment to-date been in DNAP? What share of DNAP is owned by TBF for their investment? Do they have any warrants to buy any more shares prior to the company going public or later? Are there any restrictions placed on the shares/warrants held by TBF? Is any portion of the shares in escrow planned to be allocated to DNAP for their public relations work or any other role? If yes, what are the performance criteria for such an allocation?
* Is TBF expected to be involved in the second round of financing for DNAP? If yes, what is the extent of the commitment, and is it contingent on some performance measures from DNAP? (If yes, what are they?). Does TBF have the right of first refusal in the second or subsequent round of financing?
* Who are the major or institutional investors in DNAP to-date?
* Are there safeguards (poison pills) built into any DNAP agreements has, and/or employment contracts to prevent hostile take-overs?
* What are the incentives for the key employees to encourge them to continue at DNAP? (What prevents them from leaving the firm?).
* When would the existing patents of DNAP expire?
* What are the competitive advantages or distinctive features currently enjoyed by DNAP products/services compared to those of other firms in the field?
* Who are the competitors for DNAP both in USA and abroad?
* What are the plans of the management to enhance shareholder value in the next two years? What are the projected major milestones in the growth of DNAP that investors can look forward to?
* What is the marketing potential of the services/products developed or offered by DNAP both in USA and internationally? What kind of marketing or distribution channels would DNAP need to achieve projected/potential growth? Would DNAP be developing branding or would they be co-branding their products/services (for example: with Orchid)?
* What are the challenges that face DNAP today? How would the nature of these challenges change if DNAP becomes much (say ten times)larger? (resources like personnel, software, hardware, manufacturing facilities, marketing/distribution channels, and time constraints).
* What are the critical success factors in the development of the DNAP?
* If DNAP should fail as a firm, what are likely to be the chief contributing factors?
* If the price of the DNAP shares should drop further, are there any plans for a management buy back of the shares from public and take the company private? Would management ever consider a buy back of a part of the float to support the stock price?
* Are there any circumstances under which management would be willing to consider merger with a larger company?
Till later!
AI
